Keros Therapeutics (NASDAQ:KROS) Earns Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS) in a report released on Friday morning,Benzinga reports.

KROS has been the subject of a number of other research reports. Jefferies Financial Group began coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Scotiabank initiated coverage on shares of Keros Therapeutics in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Guggenheim started coverage on Keros Therapeutics in a research note on Monday, September 23rd. They issued a “buy” rating and a $96.00 price target for the company. Finally, Bank of America cut their price objective on Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research note on Thursday, September 12th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $88.89.

Keros Therapeutics Stock Performance

Keros Therapeutics stock opened at $55.92 on Friday. Keros Therapeutics has a 12 month low of $27.31 and a 12 month high of $73.00. The stock’s 50-day moving average is $59.30 and its 200-day moving average is $52.26.

Keros Therapeutics (NASDAQ:KROS) last announced its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The company had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s revenue for the quarter was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($1.33) EPS. Sell-side analysts expect that Keros Therapeutics will post -5.28 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. increased its position in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of Keros Therapeutics by 14.5% during the first quarter. Ameritas Investment Partners Inc. now owns 2,560 shares of the company’s stock worth $169,000 after acquiring an additional 324 shares during the last quarter. KBC Group NV increased its holdings in shares of Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after acquiring an additional 432 shares during the period. Point72 Asia Singapore Pte. Ltd. lifted its position in Keros Therapeutics by 36.7% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,844 shares of the company’s stock valued at $223,000 after purchasing an additional 1,033 shares during the last quarter. Finally, Arizona State Retirement System boosted its stake in Keros Therapeutics by 16.3% during the 2nd quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after purchasing an additional 1,130 shares during the period. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.